Exelixis (EXEL, Biotech) Stock Valuation & Fair Value
Mixed on our testsExelixis (EXEL, Biotech) trades at a current P/E of 19.1, about 26% below its historical normal valuation, with a forward growth estimate of 16.4% and a PEG of 1.16. Analysts' one-year estimates have been hit 9% of the time. Priced at its historical normal P/E of 25.9 on the same blended earnings, the 2026-11-06 close of $69.57 corresponds to about $94.40 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $69.57 at the Nov 6 close, 6.0% above the 20-day average ($65.63) and 14.2% above the 50-day ($60.92).
- RSI (14) at 66.1.
- 52-week range $40.74 to $72.75: the price is 4.4% below the high and 70.8% above the low.
The Street vs SeerForecast
Wall Street's mean price target for EXEL is $59.79 across 14 analysts, 14.1% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating moved from favorable on our tests (2026-07-31) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-10-19, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 29 readings
Frequently asked questions
Is Exelixis stock overvalued?
At a current P/E of 19.1 versus its historical normal P/E of 25.9, Exelixis trades about 26% below its typical valuation, with a PEG of 1.16 on 16.4% forward growth. tickerseer currently rates it mixed on our tests.
What is Exelixis's fair value and PEG?
Exelixis trades at a current P/E of 19.1 against a historical normal P/E of 25.9, a PEG of 1.16, and a forward growth estimate of 16.4%. Priced at its historical normal P/E of 25.9 on the same blended earnings, the 2026-11-06 close of $69.57 corresponds to about $94.40 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Exelixis changed?
tickerseer's rating moved from favorable on our tests (2026-07-31) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-10-19, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Exelixis?
The mean Wall Street price target for Exelixis is $59.79 across 14 analysts, 14.1% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.